Indivior Pharmaceuticals (INDV) Operating Expenses (2024 - 2026)

Indivior Pharmaceuticals' Operating Expenses history runs 3 years deep, the most recent figure standing at $139.0 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 10.9% year-over-year to $139.0 million; the TTM figure through Mar 2026 stood at $17.0 million (down 98.12% YoY), while the FY2025 annual figure was $34.0 million, down 96.3% from the prior year.
• Operating Expenses was $139.0 million for Q1 2026 at Indivior Pharmaceuticals, up from -$487.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $338.0 million in Q2 2024 to a low of -$487.0 million in Q4 2025.
• Historically, Operating Expenses has averaged $121.4 million across 3 years, with a median of $178.0 million in 2025.
• Biggest YoY gain for Operating Expenses was 8.77% in 2025; the steepest drop was 337.56% in 2025.
• A 3-year view of Operating Expenses shows it stood at $205.0 million in 2024, then tumbled by 337.56% to -$487.0 million in 2025, then jumped by 128.54% to $139.0 million in 2026.
• The last three Operating Expenses figures came in at $139.0 million (Q1 2026), -$487.0 million (Q4 2025), and $187.0 million (Q3 2025), per Business Quant data.